Back to results
US 2023/0068949 A1Published application
New mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy
AssigneeCellectis
InventorsCecile SCHIFFER-MANNIOUI, Philippe DUCHATEAU
Life of this patent
Estimating the term…
Abstract
The present invention relates to engineered immune cells expressing new mesothelin (MLSN) specific chimeric antigen receptors (anti-mesothelin CAR) and their use in the treatment of solid tumors, particularly suited for allogeneic cell immunotherapy.
Claims48
A mesothelin specific chimeric antigen receptor (CAR) comprising at least:
- an extracellular ligand binding-domain comprising VH and VL from a monoclonal anti-mesothelin antibody;
- a transmembrane domain;
- and
- a cytoplasmic domain comprising a CD3 zeta signalling domain and a co-stimulatory domain
- wherein said extra cellular ligand binding-domain is directed against the MSLN antigen polypeptide region SEQ ID NO:25.
2 more elements
Dependencies are inferred from the claim text.